ALemtuzumab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4187 publications

First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.

First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 06, 2026

Violaceous Nodules on the Leg of an Alemtuzumab-Treated Kidney Transplant Recipient: Answer.

Violaceous Nodules on the Leg of an Alemtuzumab-Treated Kidney Transplant Recipient: Answer.

Journal: The American Journal of dermatopathology

Published: February 17, 2026

Violaceous Nodules on the Leg of an Alemtuzumab-Treated Kidney Transplant Recipient: Challenge.

Violaceous Nodules on the Leg of an Alemtuzumab-Treated Kidney Transplant Recipient: Challenge.

Journal: The American Journal of dermatopathology

Published: February 17, 2026

Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: A multicenter prospective study.

Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: A multicenter prospective study.

Journal: Blood advances

Published: January 05, 2026

A case of T-prolymphocytic leukemia harboring RAS mutation.

A case of T-prolymphocytic leukemia harboring RAS mutation.

Journal: Annals of hematology

Published: December 31, 2025

Managing reactivation of multiple sclerosis during treatment with natalizumab.

Managing reactivation of multiple sclerosis during treatment with natalizumab.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: December 20, 2025

The comparative efficacy of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis: Updated meta-regression estimates by patient subgroup.

The comparative efficacy of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis: Updated meta-regression estimates by patient subgroup.

Journal: Multiple sclerosis and related disorders

Published: December 20, 2025

Anti-CD52 therapy of rheumatic diseases: Revisited in the era of immune reset.

Anti-CD52 therapy of rheumatic diseases: Revisited in the era of immune reset.

Journal: Autoimmunity reviews

Published: December 19, 2025

Interleukin-2 Receptor Antagonist Induction Therapy in Lung Transplantation-A Meta-Analysis of Reconstructed Time-to-Event Data.

Interleukin-2 Receptor Antagonist Induction Therapy in Lung Transplantation-A Meta-Analysis of Reconstructed Time-to-Event Data.

Journal: Journal of clinical medicine

Published: December 14, 2025

Appendicitis and multiple sclerosis disease-modifying therapies: a disproportionality analysis of the FDA adverse event reporting system.

Appendicitis and multiple sclerosis disease-modifying therapies: a disproportionality analysis of the FDA adverse event reporting system.

Journal: Multiple sclerosis and related disorders

Published: December 12, 2025

Single-cell transcriptomic mendelian randomization and co-localization reveal immune-mediated regulatory mechanisms and drug targets in atopic dermatitis.

Single-cell transcriptomic mendelian randomization and co-localization reveal immune-mediated regulatory mechanisms and drug targets in atopic dermatitis.

Journal: International immunopharmacology

Published: December 10, 2025

Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.

Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.

Journal: The New England journal of medicine

Published: December 09, 2025

Showing 1-12 of 4,187

Last Updated: 04/28/2026